Re: News Releases - Wednesday, March 15, 2000
Aradigm Retains Cryopak To Develop Temperature Sensitive Packing
Solutions For Revolutionary Pulmonary Insulin Product Being Developed
With Novo Nordisk
===========================================================================
Cryopak Industries Inc. has been retained by Aradigm, a California-based
pharmaceutical technology company developing innovative new ways for
patients to self-administer medication. Cryopak Corporation, 100% owned
subsidiary of Cryopak Industries, will be developing packing systems to
ship Aradigm's temperature sensitive products worldwide.
"We are extremely excited about this partnership. It is another step in a
field in which Cryopak has been rapidly expanding. It gives us the
opportunity to develop complete packing solutions and operating procedures
for a leading edge company," said John Morgan, President and CEO of Cryopak
Corp.
Aradigm's innovative products enable people to take drugs such as insulin
by inhaling the medicine, which is then absorbed into the bloodstream
through the lungs. The proprietary technology eliminates the need for
needles and pills. Aradigm is currently developing these systems, for
worldwide shipments of insulin, in conjunction with Novo Nordisk A/S, the
world leader in insulin and diabetes care.
"We were really impressed with the Cryopak product and the packaging
potential as it applies to temperature sensitive product delivery," says
Carlo Massucci, Manager of Warehousing and Logistics, Aradigm Corporation.
"Cryopak showed creativity in their design capabilities, cost effectiveness
and materials sourcing."
Located in Hayward, California, Aradigm is engaged in the development of
novel pulmonary drug delivery systems designed to enhance the delivery and
effectiveness of existing and development stage drugs, reducing the need
for injectable therapy. The company is currently working with several large
pharmaceutical companies and its multiple collaborations address a variety
of disease situations potentially benefiting large patient populations
worldwide. More information is available about the company on its web site
at aradigm.com
Cryopak Industries Inc. develops, manufactures and markets
temperature-controlling products and packing systems for the transport of
pharmaceuticals, seafood, airline food and beverages, temperature sensitive
perishables, and for Internet directed retail and commercial shopping
networks. The Company is headquartered in Vancouver, British Columbia and
is traded on the Canadian Venture Exchange under the symbol CII. For more
information about Cryopak Industries Inc. or its patented products, visit
the company's web site at cryopak.com or call toll-free (800)
667-2532.
The Canadian Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
On Behalf Of The Board Of Directors
Harry Bygdnes, President
For further information please contact:
Adam Rabiner, Investor Relations Manager
Cryopak Industries Inc.:(800) 667-2532 or (604) 685-3616
===========================================================================
Copyright (c) 2000 CRYOPAK INDUSTRIES INC. (CII) All rights reserved. For
more information visit our website at cryopak.com or send
mailto:cryopak@cryopak.com |
